RPRX News
  • FDA Schedules Type B Pre-NDA Meeting With Repros
    9/26/2014
  • Repros Reports Positive Top Line Results From Second Pivotal Study Of Androxal
    9/25/2014
  • Repros Therapeutics Q2 Loss Per Share $0.38, Inline With Last Year
    8/11/2014
  • Repros Says Fully Enrolls Second Head To Head Study Of Androxal Versus Topical Testosterone Gel
    5/13/2014

Next 10 Headlines